{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:31:37Z","timestamp":1793413897299,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s43441-026-01041-8","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:49:02Z","timestamp":1788011342000},"page":"1637-1647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-Oncology Biomarkers in Precision Medicine: A Narrative Review"],"prefix":"10.1007","volume":"60","author":[{"given":"Achilleas","family":"Livieratos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Goea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Karelle","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarantis","family":"Chlamydas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasree","family":"Purkayastha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslihan","family":"Gerhold-Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schlieker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Cardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Gaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"1041_CR1","unstructured":"Deglincerti A, Laing R. Precision medicine beyond oncology. Drug Target Review. 2020. https:\/\/www.drugtargetreview.com\/article\/77377\/precision-medicine-beyond-oncology\/ [Accessed 2025 Dec 10]."},{"key":"1041_CR2","doi-asserted-by":"publisher","first-page":"878942","DOI":"10.3389\/fmed.2022.878942","volume":"9","author":"NM Hendrikse","year":"2022","unstructured":"Hendrikse NM, Llinares Garcia J, Vetter T, Humphreys AJ, Ehmann F. Biomarkers in medicines development-from discovery to regulatory qualification and beyond. Front Med (Lausanne). 2022;9:878942.","journal-title":"Front Med (Lausanne)"},{"issue":"20","key":"1041_CR3","first-page":"1617","volume":"141","author":"AR Chapman","year":"2020","unstructured":"Chapman AR, Adamson PD, Shah ASV, Anand A, Strachan FE, Ferry AV, et al. High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation. 2020;141(20):1617\u201320.","journal-title":"Circulation"},{"issue":"7","key":"1041_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jchf.2018.02.008","volume":"6","author":"JL Januzzi","year":"2018","unstructured":"Januzzi JL. Will Biomarkers Succeed as a surrogate endpoint in heart failure trials? JACC Heart Fail. 2018;6(7):570\u20132.","journal-title":"JACC Heart Fail"},{"issue":"7","key":"1041_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jchf.2018.02.007","volume":"6","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, et al. Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure. JACC Heart Fail. 2018;6(7):564\u20139.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"1041_CR6","first-page":"e009427","volume":"15","author":"P Welsh","year":"2022","unstructured":"Welsh P, Campbell RT, Mooney L, Kimenai DM, Hayward C, Campbell A, et al. Reference ranges for NT-proBNP and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circ Heart Fail. 2022;15(6):e009427.","journal-title":"Circ Heart Fail"},{"key":"1041_CR7","doi-asserted-by":"crossref","unstructured":"Maltsev D, Tyravska Y, Shpryakha Y, Kaminskyy V, Merzliak S. Individualised medicine: application of a personalised approach in clinical practice. J Pioneering Med Sci. 2025;14(6):7\u201319. https:\/\/jpmsonline.com\/article\/individualised-medicine-application-of-a-personalised-approach-in-clinical-practice-750 [Accessed 2025 Dec 10].","DOI":"10.47310\/jpms2025140602"},{"issue":"1","key":"1041_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237\u201344.","journal-title":"Kidney Int"},{"issue":"6","key":"1041_CR9","first-page":"632","volume":"12","author":"RR Van Kimmenade","year":"2010","unstructured":"Van Kimmenade RR, Martens RJ, De Boer D, Brankovic M, Cramer MJ, De Leeuw PW, et al. Utility of renal biomarkers in acute cardiac care. Eur J Heart Fail. 2010;12(6):632\u20135.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1041_CR10","doi-asserted-by":"publisher","first-page":"F552","DOI":"10.1152\/ajprenal.00285.2002","volume":"286","author":"T Ichimura","year":"2004","unstructured":"Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Ren Physiol. 2004;286(3):F552\u201363.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1041_CR11","doi-asserted-by":"publisher","unstructured":"Karger AB, Shlipak MG. Glomerular Filtration Rate (GFR) Estimation with cystatin C-past, present, and future. Clin Chem. 2025. https:\/\/doi.org\/10.1093\/clinchem\/hvae047","DOI":"10.1093\/clinchem\/hvae047"},{"issue":"6","key":"1041_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","volume":"14","author":"VB Kraus","year":"2018","unstructured":"Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"1041_CR13","doi-asserted-by":"publisher","first-page":"868658","DOI":"10.3389\/fcvm.2022.868658","volume":"9","author":"EYM Chung","year":"2022","unstructured":"Chung EYM, Trinh K, Li J, Hahn SH, Endre ZH, Rogers NM, et al. Biomarkers in cardiorenal syndrome and potential insights into novel therapeutics. Front Cardiovasc Med. 2022;9:868658.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1041_CR14","doi-asserted-by":"publisher","first-page":"e000390","DOI":"10.1136\/bmjno-2022-000395","volume":"5","author":"FJ Meda","year":"2023","unstructured":"Meda FJ, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Sauer M, et al. Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid. BMJ Neurol Open. 2023;5(1):e000390.","journal-title":"BMJ Neurol Open"},{"key":"1041_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/BMI.S38440","volume":"11","author":"SI Sherwani","year":"2016","unstructured":"Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95\u2013104.","journal-title":"Biomark Insights"},{"issue":"5","key":"1041_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/fca.15.39","volume":"11","author":"J MacNamara","year":"2015","unstructured":"MacNamara J, Eapen DJ, Quyyumi A, Sperling L. Novel biomarkers for cardiovascular risk assessment: current status and future directions. Future Cardiol. 2015;11(5):597\u2013613.","journal-title":"Future Cardiol"},{"issue":"16","key":"1041_CR17","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.3390\/jcm13164627","volume":"13","author":"AM Vrabie","year":"2024","unstructured":"Vrabie AM, Totolici S, Delcea C, Badila E. Biomarkers in heart failure with preserved ejection fraction: a perpetually evolving frontier. J Clin Med. 2024;13(16):4627.","journal-title":"J Clin Med"},{"issue":"9","key":"1041_CR18","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/biomedicines11092444","volume":"11","author":"E Amezcua-Castillo","year":"2023","unstructured":"Amezcua-Castillo E, Gonz\u00e1lez-Pacheco H, S\u00e1enz-San Mart\u00edn A, M\u00e9ndez-Ocampo P, Gutierrez-Moctezuma I, Mass\u00f3 F, et al. C-Reactive Protein: The quintessential marker of systemic inflammation in coronary artery disease-advancing toward precision medicine. Biomedicines. 2023;11(9):2444.","journal-title":"Biomedicines"},{"issue":"1","key":"1041_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","volume":"96","author":"RT Gansevoort","year":"2019","unstructured":"Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019;96(1):159\u201369.","journal-title":"Kidney Int"},{"issue":"2","key":"1041_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5527\/wjn.v7.i2.51","volume":"7","author":"M Tasneem","year":"2018","unstructured":"Tasneem M, Mannix C, Wong A, Zhang J, Rangan G. Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease? World J Nephrol. 2018;7(2):51\u20137.","journal-title":"World J Nephrol"},{"issue":"11","key":"1041_CR21","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1093\/ckj\/sfad118","volume":"16","author":"S Arjune","year":"2023","unstructured":"Arjune S, Oehm S, Todorova P, Gansevoort RT, Bakker SJL, Erger F, et al. Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study. Clin Kidney J. 2023;16(11):2194\u2013204.","journal-title":"Clin Kidney J"},{"key":"1041_CR22","doi-asserted-by":"publisher","unstructured":"Alakwaa F, Das V, Majumdar A, Nair V, Fermin D, Dey AB et al. Leveraging complementary multi-omics data integration methods for mechanistic insights in kidney diseases. JCI Insight. 2025;10(5):e186070. https:\/\/doi.org\/10.1172\/jci.insight.186070","DOI":"10.1172\/jci.insight.186070"},{"key":"1041_CR23","doi-asserted-by":"publisher","unstructured":"Das V, Narayanan S, Zhang X, Bergman O, Djordjevic D, Kronqvist M et al. Multi-omics data integration from patients with carotid stenosis illuminates key molecular signatures of atherosclerotic instability. medRxiv [Preprint]. 2025; https:\/\/doi.org\/10.1101\/2025.05.12.25327328","DOI":"10.1101\/2025.05.12.25327328"},{"key":"1041_CR24","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.ebiom.2023.104635","volume":"93","author":"F Bienaim\u00e9","year":"2023","unstructured":"Bienaim\u00e9 F, Muorah M, Metzger M, Broeuilh M, Houillier P, Flamant M, et al. Combining robust urine biomarkers to assess chronic kidney disease progression. eBioMedicine. 2023;93:104635.","journal-title":"eBioMedicine"},{"issue":"11","key":"1041_CR25","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1016\/j.ekir.2024.08.004","volume":"9","author":"M Postacioglu","year":"2024","unstructured":"Postacioglu M, Katz R, Ascher SB, Hall T, Garimella PS, Hallan SI, et al. Associations of urine epidermal growth factor with kidney and cardiovascular outcomes in individuals with CKD in SPRINT. Kidney Int Rep. 2024;9(11):3167\u201376.","journal-title":"Kidney Int Rep"},{"issue":"14","key":"1041_CR26","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","volume":"359","author":"G F\u00e4tkenheuer","year":"2008","unstructured":"F\u00e4tkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359(14):1442\u201355.","journal-title":"N Engl J Med"},{"issue":"14","key":"1041_CR27","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429\u201341.","journal-title":"N Engl J Med"},{"issue":"9","key":"1041_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2165\/11203940-000000000-00000","volume":"70","author":"CM Perry","year":"2010","unstructured":"Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs. 2010;70(9):1189\u2013213.","journal-title":"Drugs"},{"issue":"7","key":"1041_CR29","doi-asserted-by":"publisher","first-page":"e0389523","DOI":"10.1128\/spectrum.03895-23","volume":"12","author":"S Gracias","year":"2024","unstructured":"Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C, et al. In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study. Microbiol Spectr. 2024;12(7):e0389523.","journal-title":"Microbiol Spectr"},{"key":"1041_CR30","first-page":"5447","volume":"9","author":"SM Woollard","year":"2015","unstructured":"Woollard SM, Kanmogne GD. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015;9:5447\u201368.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"1041_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O\u2019Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849\u201357.","journal-title":"JAMA"},{"issue":"16","key":"1041_CR32","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821\u201330.","journal-title":"JAMA"},{"key":"1041_CR33","unstructured":"U.S. Food and Drug Administration. Surrogate Endpoint Resources for Drug and Biologic Development [Internet]. Silver Spring (MD): FDA. 2018 [Accessed 2025 Dec 10]. https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development"},{"issue":"3","key":"1041_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"1041_CR35","unstructured":"U.S. Food and Drug Administration. Clinical Outcome Assessment (COA) Compendium [Internet]. Silver Spring (MD): FDA; 2021 [Accessed 2025 Dec 10]. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/clinical-outcome-assessment-compendium"},{"issue":"8","key":"1041_CR36","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jama.282.8.790","volume":"282","author":"R Temple","year":"1999","unstructured":"Temple R. Are Surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999;282(8):790\u20135.","journal-title":"JAMA"},{"key":"1041_CR37","unstructured":"The Food and Drug Administration Modernization Act of 1997. Title 21 Code of Federal Regulations Part 314 Subpart H Sect.\u00a0 314.500. 1997."},{"key":"1041_CR38","unstructured":"European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC). No 507\/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004 [Internet]. Amsterdam: EMA; 2006 [Accessed 2025 Dec 10]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-scientific-application-and-practical-arrangements-necessary-implement-commission-regulation-ec-no-5072006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf"},{"key":"1041_CR39","unstructured":"FDA Center for Drug Evaluation and Research. Memorandum to the File BLA 125085 Avastin (bevacizumab). 2010."},{"issue":"23","key":"1041_CR40","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1056\/NEJMp2412068","volume":"391","author":"B Kanapuru","year":"2024","unstructured":"Kanapuru B, Carioti T, Gormley N, Pazdur R. Autopsy of a drug withdrawal \u2014 the case of melphalan flufenamide. N Engl J Med. 2024;391(23):2177\u20139.","journal-title":"N Engl J Med"},{"key":"1041_CR41","unstructured":"Food US, and Drug Administration. Withdrawn | Cancer Accelerated Approvals [Internet]. Silver Spring (MD): FDA; 2024 [Accessed 2025 Dec 10]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals"},{"issue":"2","key":"1041_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1541-0420.2008.01106.x","volume":"65","author":"MM Joffe","year":"2009","unstructured":"Joffe MM, Greene T. Related causal frameworks for surrogate outcomes. Biometrics. 2009;65(2):530\u20138.","journal-title":"Biometrics"},{"issue":"4","key":"1041_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"RL Prentice","year":"1989","unstructured":"Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431\u201340.","journal-title":"Stat Med"},{"issue":"2","key":"1041_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00001648-199203000-00013","volume":"3","author":"JM Robins","year":"1992","unstructured":"Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992;3(2):143\u201355.","journal-title":"Epidemiology"},{"issue":"1","key":"1041_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.0006-341X.2002.00021.x","volume":"58","author":"CE Frangakis","year":"2002","unstructured":"Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58(1):21\u20139.","journal-title":"Biometrics"},{"issue":"1","key":"1041_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","volume":"1","author":"M Buyse","year":"2000","unstructured":"Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1(1):49\u201367.","journal-title":"Biostatistics"},{"issue":"4","key":"1041_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.284.4.465","volume":"284","author":"HM Perry","year":"2000","unstructured":"Perry HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the systolic hypertension in the elderly program (SHEP). JAMA. 2000;284(4):465\u201371.","journal-title":"JAMA"},{"key":"1041_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2019.01.001","volume":"283","author":"P Barter","year":"2019","unstructured":"Barter P, Genest J. HDL cholesterol and ASCVD risk stratification: a debate. Atherosclerosis. 2019;283:7\u201312.","journal-title":"Atherosclerosis"},{"key":"1041_CR49","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration, US. (); 2016 [Accessed 2025 Dec 10]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"issue":"22","key":"1041_CR50","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1177\/15353702211002153","volume":"246","author":"JM Sauer","year":"2021","unstructured":"Sauer JM, Porter AC. Qualification of translational safety biomarkers. Exp Biol Med (Maywood). 2021;246(22):2391\u20138.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"21","key":"1041_CR51","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2007.02.052","volume":"49","author":"PM Ridker","year":"2007","unstructured":"Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49(21):2129\u201338.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1041_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11886-022-01834-x","volume":"25","author":"JD Mitchell","year":"2023","unstructured":"Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al. Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology. Curr Cardiol Rep. 2023;25(3):133\u201346.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"1041_CR53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ckj\/sfs013","volume":"5","author":"S Uchino","year":"2012","unstructured":"Uchino S, Bellomo R, Goldsmith D. The meaning of the blood urea nitrogen\/creatinine ratio in acute kidney injury. Clin Kidney J. 2012;5(2):187\u201391.","journal-title":"Clin Kidney J"},{"key":"1041_CR54","doi-asserted-by":"crossref","unstructured":"Christofides EA, Desai N. Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211003683.","DOI":"10.1177\/21501327211003683"},{"key":"1041_CR55","unstructured":"Food US, Administration D, Reviews. Qualification of Biomarker: Clusterin (CLU), Cystatin-C (CysC), Kidney Injury Molecule-1 (KIM-1), N-acetyl-beta-D-glucosaminidase (NAG), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and Osteopontin (OPN) [Internet]. Silver Spring (MD): FDA; 2020 [Accessed 2025 Dec 10]. Available from: https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/reviews-qualification-biomarker-clusterin-clu-cystatin-c-cysc-kidney-injury-molecule-1-kim-1-n"},{"key":"1041_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.resuscitation.2019.06.008","volume":"141","author":"D Titeca-Beauport","year":"2019","unstructured":"Titeca-Beauport D, Diouf M, Daubin D, Chelly J, Vong LV, Maizel J, et al. The urine biomarkers TIMP2 and IGFBP7 can identify patients who will experience severe acute kidney injury following a cardiac arrest: a prospective multicentre study. Resuscitation. 2019;141:104\u201310.","journal-title":"Resuscitation"},{"issue":"2","key":"1041_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.7150\/ntno.108320","volume":"9","author":"S Pandey","year":"2025","unstructured":"Pandey S, Singh A, Kumar A. Metabolomics for the identification of biomarkers in kidney diseases. Nanotheranostics. 2025;9(2):110\u201320.","journal-title":"Nanotheranostics"},{"issue":"18","key":"1041_CR58","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.3390\/diagnostics13182967","volume":"13","author":"R Chinnappan","year":"2023","unstructured":"Chinnappan R, Al Attrach I, Al-Mohannadi M, Al-Sulaiti A, Bansod S, Abu-Salah KM, et al. Low-cost point-of-care monitoring of ALT and AST is promising for faster decision making and diagnosis of acute liver injury. Diagnostics (Basel). 2023;13(18):2967.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"1041_CR59","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1183\/13993003.00699-2016","volume":"48","author":"L Lehtim\u00e4ki","year":"2016","unstructured":"Lehtim\u00e4ki L, Csonka P, M\u00e4kinen E, Haarala A. Predictive value of exhaled nitric oxide in the management of asthma: a systematic review. Eur Respir J. 2016;48(3):706\u201314.","journal-title":"Eur Respir J"},{"issue":"1","key":"1041_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000519920","volume":"53","author":"D Lam","year":"2022","unstructured":"Lam D, Nadkarni GN, Mosoyan G, Neal B, Mahaffey KW, Rosenthal N, et al. Clinical utility of KidneyIntelX in early stages of diabetic kidney disease in the CANVAS trial. Am J Nephrol. 2022;53(1):21\u201331.","journal-title":"Am J Nephrol"},{"issue":"3","key":"1041_CR61","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/jcm11030857","volume":"11","author":"P Severino","year":"2022","unstructured":"Severino P, D\u2019Amato A, Prosperi S, Dei Cas A, Mattioli AV, Cevese A, et al. Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity? J Clin Med. 2022;11(3):857.","journal-title":"J Clin Med"},{"issue":"4","key":"1041_CR62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/geriatrics10040104","volume":"10","author":"M Jarocki","year":"2025","unstructured":"Jarocki M, Green S, Wu HHL, Chinnadurai R. Cardiorenal syndrome in the elderly: challenges and considerations. Geriatr (Basel). 2025;10(4):104.","journal-title":"Geriatr (Basel)"},{"issue":"5","key":"1041_CR63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41569-024-01010-4","volume":"21","author":"AH Gunn","year":"2024","unstructured":"Gunn AH, Pendyal A. Novel cardiovascular therapeutics and the risk of financial toxicity. Nat Rev Cardiol. 2024;21(5):349\u201350.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"1041_CR64","doi-asserted-by":"publisher","first-page":"e030131","DOI":"10.1161\/JAHA.123.030131","volume":"13","author":"JI Barzilay","year":"2024","unstructured":"Barzilay JI, Farag YMK, Durthaler J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J Am Heart Assoc. 2024;13(2):e030131.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1041_CR65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13613-024-01360-9","volume":"14","author":"M Ostermann","year":"2024","unstructured":"Ostermann M, Legrand M, Meersch M, Srisawat N, Zarbock A, Kellum JA. Biomarkers in acute kidney injury. Ann Intensive Care. 2024;14(1):145.","journal-title":"Ann Intensive Care"},{"issue":"8","key":"1041_CR66","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ki.2011.198","volume":"80","author":"RG Fassett","year":"2011","unstructured":"Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806\u201321.","journal-title":"Kidney Int"},{"issue":"20","key":"1041_CR67","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMra0800239","volume":"358","author":"E Braunwald","year":"2008","unstructured":"Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148\u201359.","journal-title":"N Engl J Med"},{"issue":"3","key":"1041_CR68","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.ijcard.2013.01.228","volume":"168","author":"J Lassus","year":"2013","unstructured":"Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the multinational observational cohort on acute heart failure (MOCA) study. Int J Cardiol. 2013;168(3):2186\u201394.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1041_CR69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1053\/j.ajkd.2023.07.012","volume":"83","author":"EA Kiernan","year":"2024","unstructured":"Kiernan EA, Hu D, Philbrook HT, Ix JH, Bonventre JV, Coca SG, et al. Urinary biomarkers and kidney injury in VA NEPHRON-D: phenotyping acute kidney injury in clinical trials. Am J Kidney Dis. 2024;83(2):151\u201361.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1041_CR70","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/jcm11030857","volume":"11","author":"P Severino","year":"2022","unstructured":"Severino P, D\u2019Amato A, Prosperi S, Dei Cas A, Mattioli AV, Cevese A, et al. Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity? J Clin Med. 2022;11(3):857.","journal-title":"J Clin Med"},{"issue":"7","key":"1041_CR71","first-page":"e41252","volume":"15","author":"AO Ajibowo","year":"2023","unstructured":"Ajibowo AO, Okobi OE, Emore E, Soladoye E, Sike CG, Odoma VA, et al. Cardiorenal syndrome: Literature Rev Cureus. 2023;15(7):e41252.","journal-title":"Cardiorenal Syndrome: Literature Rev Cureus"},{"issue":"17","key":"1041_CR72","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108(17):2154\u201369.","journal-title":"Circulation"},{"key":"1041_CR73","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.hlc.2025.05.094","volume":"34","author":"V Chopra","year":"2025","unstructured":"Chopra V, Khan MS, Abdelhamid M, Abraham WT, Amir O, Anker SD, et al. iCARDIO Alliance global implementation guidelines on heart failure 2025. Heart Lung Circ. 2025;34:e55\u201382.","journal-title":"Heart Lung Circ"},{"issue":"Suppl 1","key":"1041_CR74","first-page":"1","volume":"21","author":"Y \u00c7avu\u015fo\u011flu","year":"2019","unstructured":"\u00c7avu\u015fo\u011flu Y, Alper AT, Altay H, \u00c7elik A, Demirkan B, G\u00fcven\u00e7 TS, et al. Natriuretic peptides in clinical practice. Anatol J Cardiol. 2019;21(Suppl 1):1\u201340.","journal-title":"Anatol J Cardiol"},{"issue":"7","key":"1041_CR75","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/ijms26073218","volume":"26","author":"VR Netala","year":"2025","unstructured":"Netala VR, Hou T, Wang Y, Zhang Z, Teertam SK. Cardiovascular biomarkers: tools for precision diagnosis and prognosis. Int J Mol Sci. 2025;26(7):3218.","journal-title":"Int J Mol Sci"},{"key":"1041_CR76","doi-asserted-by":"publisher","first-page":"111458","DOI":"10.1016\/j.jclinane.2024.111458","volume":"95","author":"C Strau\u00df","year":"2024","unstructured":"Strau\u00df C, Booke H, Forni L, Zarbock A. Biomarkers of acute kidney injury: from discovery to the future of clinical practice. J Clin Anesth. 2024;95:111458.","journal-title":"J Clin Anesth"},{"key":"1041_CR77","doi-asserted-by":"crossref","unstructured":"Stopic B, Medic-Brkic B, Savic-Vujovic K, Davidovic Z, Todorovic J, Dimkovic N. Biomarkers and predictors of adverse cardiovascular events in different stages of chronic kidney disease. Dose Response. 2022 Jul-Sep;20(3):15593258221127568.","DOI":"10.1177\/15593258221127568"},{"issue":"8","key":"1041_CR78","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/jpm15080370","volume":"15","author":"PF Lavere","year":"2025","unstructured":"Lavere PF, Phillips KM, Hanania NA, Adrish M. Established and emerging asthma biomarkers with a focus on biologic trials: a narrative review. J Pers Med. 2025;15(8):370.","journal-title":"J Pers Med"},{"issue":"1","key":"1041_CR79","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12931-025-03356-w","volume":"26","author":"C Xie","year":"2025","unstructured":"Xie C, Wang K, Yang K, Zhong Y, Gul A, Luo W, et al. Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits. Respir Res. 2025;26(1):274.","journal-title":"Respir Res"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01041-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:44Z","timestamp":1793412164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01041-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01041-8","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.G., V.D., M.K.R., S.C., A.G.-A., L.S., and G.J. are employees of or consultants to pharmaceutical or biotechnology companies. A.L. and M.G. declare no competing interests. D.P. and M.C. are employees of AstraZeneca, and may or may own stock options.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}